Trial Profile

Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Pioglitazone (Primary) ; Bosutinib; Dasatinib; Imatinib; Nilotinib; Ponatinib
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms ACTIW

06 Aug 2020 Planned End Date changed from 1 Jun 2021 to 1 Jun 2023.
06 Aug 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2022.
23 May 2018 Avelumab has been added in the treatments.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com